Category Archives: pricing
By Guest Blogger | Published: May 21, 2014
Global price management will lead the fight-back on margins, writes Arnaud Grunwald. Price erosion, falling sales and dwindling product pipelines — they are all inflicting pain on boardrooms in the pharma industry. What a gloomy outlook, you might think. But it is out of this dark cloud that global price management is emerging as a […]
By Guest Blogger | Published: May 12, 2014
by Matthew Cook and Sebastien Morisot In light of the risks and challenges inherent in the development of oncologics, some biopharma companies are beginning to question whether oncology remains an attractive therapeutic area in which to invest limited research, development, and commercialization resources.
By Guest Blogger | Published: May 1, 2014
By Leela Barham. An administrative court has said that a Clinical Commission Group (CCG, a local budget holder for the National Health Service in England) can’t just disagree with guidance from the UK’s National Institute for Health and Clinical Excellence (NICE) — that’s unlawful.
By Guest Blogger | Published: April 25, 2014
By Leela Barham. The Incremental Cost Effectiveness Ratio (ICER) thresholds used by agencies such as the UK’s National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and as far afield as Australia by the Pharmaceutical Benefits Advisory Committee (PBAC) are often controversial. This is mostly because it means analysts saying that a […]
By Marylyn Donahue | Published: April 24, 2014
Gilead Silences has cleaned up on their new $1,000 Hepatitis C pill Sovaldi (84,000 per treatment), hauling in a record-breaking $2.3 billion in its first full quarter on the market. The previous record (also a Hepatitis C drug Incivek from Vertex) came in with $1.56 billion, according to EP Vantage. And Sovaldi may well go […]